Announcement PDF RNS Number : 4825B OptiBiotix Health PLC 31 January 2020 31 January 2020 OptiBiotix Health plc ("OptiBiotix" or the "Company") Launch of SlimBiome® in North America with Agropur Inc. OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, and Agropur Inc. ("Agropur") have announced the launch of SlimBiome in the North American market. This launch follows the announcement (RNS: 24 June 2019) that OptiBiotix granted Agropur an exclusive license to manufacture, supply and distribute OptiBiotix's SlimBiome® weight management technology in the USA, Canada and Mexico. Agropur is a wholly owned subsidiary of Agropur Cooperative, which is a North American dairy industry leader founded in 1938. With 8,800 employees and sales of US$5.5 billion in 2019, Agropur processes more than 14 billion lbs of milk per year at its 38 plants across North America. Mike Homewood, Vice President of Agropur Custom Solutions, said, "We are proud of our agreement and partnership with OptiBiotix and the exclusive opportunity to bring SlimBiome® to the North American food and nutrition industries. This ingredient solution for weight management fits into Agropur's goal to provide innovative, forward-thinking products to our customers." Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented, "We are very pleased with the progress Agropur has made since the announcement of our partnership at the end of June 2019. Over a rather short period of time, Agropur has qualified its manufacturing process and is now able to produce SlimBiome® in the USA and supply the ingredient to North American B2B customers. This is a key strategic step In OptiBiotix's commercial development as it grants the company access to the US weight management market which was estimated to be worth US$72 billion in 2019 (source: BusinessWire.com)." For further information, please contact: OptiBiotix Health plc Stephen O'Hara, Chief Executive www.optibiotix.com Contact via Walbrook below finnCap (Broker) Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) Tel: 020 7220 0500 goetzpartners securities Limited Ulrich Kinzel Tel: 0203 859 7725 Walbrook PR Ltd Anna Dunphy Mob: 07876 741 001 About OptiBiotix - www.optibiotix.com OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than 20 international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END NRAFLFVELRIIVII